Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Equillium Inc (EQ)

Equillium Inc (EQ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,981
  • Shares Outstanding, K 17,684
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,600 K
  • 60-Month Beta 2.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.35
  • Low Estimate -0.50
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -25.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.64 +269.32%
on 07/07/20
27.05 -63.96%
on 07/13/20
+6.93 (+245.13%)
since 07/06/20
3-Month
2.53 +285.38%
on 06/24/20
27.05 -63.96%
on 07/13/20
+7.07 (+264.39%)
since 05/06/20
52-Week
2.20 +343.18%
on 03/24/20
27.05 -63.96%
on 07/13/20
+6.44 (+194.56%)
since 08/06/19

Most Recent Stories

More News
Equillium to Present at BTIG Virtual Biotechnology Conference 2020

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 9.75 (-8.28%)
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

BIIB : 277.66 (+0.54%)
GILD : 68.81 (-0.28%)
MRNA : 73.76 (-2.69%)
AMGN : 241.55 (+0.03%)
RIGL : 2.46 (-2.38%)
BGNE : 224.06 (-1.30%)
EQ : 9.75 (-8.28%)
Equillium Gains From Positive Results on Coronavirus Drug

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

ALXN : 103.90 (+1.12%)
GILD : 68.81 (-0.28%)
INCY : 97.25 (-0.38%)
EQ : 9.75 (-8.28%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 7.04 (+5.39%)
ALIM : 6.88 (-1.43%)
ANVS : 5.67 (-1.05%)
AQB : 3.06 (-3.47%)
ARTL : 1.2500 (+4.17%)
AVLNF : 0.0585 (+0.86%)
BLCM : 7.49 (-0.66%)
NDRA : 0.9840 (-1.08%)
EFOI : 6.06 (+1.85%)
EQ : 9.75 (-8.28%)
EXROF : 0.6866 (-1.48%)
HL : 6.65 (+3.58%)
HSII : 20.21 (-3.94%)
HSDT : 0.5700 (-7.23%)
HGBL : 2.7700 (+2.59%)
IPWR : 7.19 (-8.87%)
LINC : 5.63 (+4.65%)
MBII : 1.1800 (+1.72%)
MLSS : 1.9200 (+2.67%)
MYSZ : 1.2700 (-5.93%)
NBEV : 2.29 (-1.29%)
ONCS : 4.20 (-0.71%)
OGEN : 1.0700 (-5.31%)
SFE : 6.00 (-1.48%)
SLS : 3.51 (-1.96%)
PIXY : 4.80 (-4.00%)
SGLB : 2.80 (-1.06%)
SOTK : 2.9900 (+0.67%)
TNXP : 1.2000 (-4.00%)
TGA : 0.6051 (+0.55%)
URG : 0.5531 (-2.14%)
Equillium to Present at Jefferies Virtual Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 9.75 (-8.28%)
Equillium Reports First Quarter 2020 Financial Results

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 9.75 (-8.28%)
Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 9.75 (-8.28%)
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced...

LPBC : 5.6200 (+0.36%)
EQ : 9.75 (-8.28%)
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today...

EQ : 9.75 (-8.28%)
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 9.75 (-8.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EQ with:

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

2nd Resistance Point 11.26
1st Resistance Point 10.50
Last Price 9.75
1st Support Level 9.32
2nd Support Level 8.90

See More

52-Week High 27.05
Fibonacci 61.8% 17.56
Fibonacci 50% 14.63
Fibonacci 38.2% 11.69
Last Price 9.75
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar